Precision Medicine Shows Promise for Reversing Early Dementia and Memory Loss
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
20 articles
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
Completed study of 102 older adults tested whether combined interventions can preserve brain volume and improve mobility through muscle-brain axis.
Small pilot study tests multicomponent behavioral program to reduce cognitive decline risk in underserved rural populations.
A structured neuroplasticity-based program improved functional performance and emotional well-being in community-dwelling older adults with dementia.
Novel movement program combining Eastern and Western exercises may help maintain independence and cognitive function in dementia patients.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
The EPICURO trial tests MERIVAยฎ turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
German researchers test whether digital environmental enrichment can boost mental and physical wellbeing in seniors through telehealth.
A completed Canadian platform trial enrolls 354 at-risk adults in a multidomain online brain health program targeting dementia prevention.
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
French researchers followed 1,028 people with mild cognitive complaints to understand how dementia develops over time.
A 210-person trial tests whether 5-month music therapy programs โ and robotic assistants โ can slow cognitive decline in older adults.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
18-month trial tested omega-3 supplementation in 774 older adults with low DHA/EPA levels and memory concerns to prevent cognitive decline.
A double-blind trial tests whether 810nm photobiomodulation can reverse cognitive impairment in long COVID patients at home.
Clinical trial explores how targeted light treatment could restore circadian rhythms and improve brain function in mild cognitive impairment.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.